Increased mammalian target of rapamycin complex 2 signaling promotes age-related decline in CD4 T cell signaling and
Eric Perkey1, Diane Fingar, Richard A Miller
1Department of Molecular, Cellular, and Developmental Biology, University of Michigan College of Literature, Science and the Arts, Ann Arbor, MI 48109;
Abstract:
CD4 T cell function declines significantly during aging. Although the mammalian target of rapamycin (TOR) has been implicated in aging, the roles of the TOR complexes (TORC1, TORC2) in the functional declines of CD4 T cells remain unknown. In this study, we demonstrate that aging increases TORC2 signaling in murine CD4 T cells, a change blocked by long-term exposure to rapamycin, suggesting that functional defects may be the result of enhanced TORC2 function. Using overexpression of Rheb to activate TORC1 and Rictor plus Sin1 to augment TORC2 in naive CD4 T cells from young mice, we demonstrated that increased TORC2, but not TORC1, signaling results in aging-associated biochemical changes. Furthermore, elevated TORC2 signaling in naive CD4 T cells from young mice leads to in vivo functional declines. The data presented in this article suggest a novel model in which aging increases TORC2 signaling and leads to CD4 T cell defects in old mice.
Insights
Aging impairs CD4 T cell function by increasing TORC2 signaling. This study reveals that enhanced TORC2 activity, not TORC1, drives age-related T cell defects, offering a new therapeutic target.
Area of Science:
- Immunology
- Aging Research
- Cellular Signaling
Background:
- CD4 T cell function deteriorates with age.
- Mammalian target of rapamycin (TOR) is linked to aging, but TORC1 and TORC2 roles in T cell aging are unclear.
Purpose of the Study:
- To investigate the roles of TORC1 and TORC2 in age-related CD4 T cell functional decline.
- To determine if increased TORC2 signaling contributes to aging-associated CD4 T cell defects.
Main Methods:
- Analyzed TORC1 and TORC2 signaling in aged murine CD4 T cells.
- Utilized Rheb overexpression for TORC1 activation and Rictor/Sin1 for TORC2 augmentation in young mouse CD4 T cells.
- Assessed in vivo function of CD4 T cells with altered TOR signaling.
Main Results:
- Aging increases TORC2 signaling in CD4 T cells, which rapamycin can block.
- Augmented TORC2, but not TORC1, signaling in young CD4 T cells mimics aging-associated biochemical changes.
- Elevated TORC2 signaling in young CD4 T cells causes in vivo functional impairments.
Conclusions:
- Aging enhances TORC2 signaling in CD4 T cells.
- Increased TORC2 activity is a key driver of age-related CD4 T cell dysfunction.
- This suggests a novel model where heightened TORC2 signaling leads to T cell defects in aged mice.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Replicative Cell Senescence
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Effect of Aging on Tissues
